

## **Technology Guidance**

# **Sitagliptin**

# for treating type 2 diabetes mellitus

**Technology Guidance from the MOH Drug Advisory Committee** 

### **Guidance Recommendations**

The Ministry of Health's Drug Advisory Committee has recommended:

✓ sitagliptin 25 mg, 50 mg and 100 mg tablets

in line with their registered indications for improving glycemic control in patients with type 2 diabetes mellitus, in view of acceptable price proposal from the manufacturer.

### **Subsidy status**

Sitagliptin 25 mg, 50 mg and 100 mg tablets are recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications.

SDL subsidy **does not** apply to combination products containing sitagliptin or other DPP-4 inhibitors.

Published: 01 Jul 2022



## **Technology Guidance**

#### **About the Agency**

The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidance, and education.

As the national HTA agency, ACE conducts evaluations to inform government subsidy decisions for treatments, diagnostic tests and vaccines, and produces guidance for public hospitals and institutions in Singapore.

This guidance is based on the evidence available to the MOH Drug Advisory Committee as at 7 Apr 2022. It is not, and should not be regarded as, a substitute for professional or medical advice. Please seek the advice of a qualified healthcare professional about any medical condition. The responsibility for making decisions appropriate to the circumstances of the individual patient remains with the healthcare professional.

Find out more about ACE at www.ace-hta.gov.sg/about

#### © Agency for Care Effectiveness, Ministry of Health, Republic of Singapore

All rights reserved. Reproduction of this publication in whole or in part in any material form is prohibited without the prior written permission of the copyright holder. Requests to reproduce any part of this publication should be addressed to:

Chief HTA Officer Agency for Care Effectiveness Email: ACE\_HTA@moh.gov.sg

In citation, please credit the "Ministry of Health, Singapore" when you extract and use the information or data from the publication.